EGF receptor as a therapeutic target (Q35179403)

7 August 2017

1 reference

title

EGF receptor as a therapeutic target (English)

1 reference

7 August 2017

Alexander Levitzki

1

1 reference

7 August 2017

publication date

1 August 2003

1 reference

7 August 2017

1 reference

7 August 2017

volume

41 Suppl 1

1 reference

7 August 2017

page(s)

S9-14

1 reference

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)00134-X

7 January 2021

The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand‐receptor interactions

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)00134-X

7 January 2021

Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)00134-X

7 January 2021

Protein tyrosine kinase inhibitors as novel therapeutic agents

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)00134-X

7 January 2021

Why the epidermal growth factor receptor? The rationale for cancer therapy

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)00134-X

7 January 2021

The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)00134-X

7 January 2021

The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target.

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)00134-X

7 January 2021

Epidermal growth factor receptor signal transactivation

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)00134-X

7 January 2021

Platelet-derived growth factor requires epidermal growth factor receptor to activate p21-activated kinase family kinases

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)00134-X

7 January 2021

EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)00134-X

7 January 2021

Transactivation of ErbB1 and ErbB2 receptors by angiotensin II in normal human prostate stromal cells

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)00134-X

7 January 2021

Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)00134-X

7 January 2021

Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)00134-X

7 January 2021

The epidermal growth factor receptor as a target for cancer therapy

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)00134-X

7 January 2021

Signal transduction interception as a novel approach to disease management

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)00134-X

7 January 2021

Epidermal‐Growth‐Factor‐Dependent Activation of the Src‐Family Kinases

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)00134-X

7 January 2021

Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)00134-X

7 January 2021

Surprise phase III failure for ZD1839.

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)00134-X

7 January 2021

HER-targeted tyrosine-kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)00134-X

7 January 2021

HER2/neu expression in malignant lung tumors

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)00134-X

7 January 2021

Potential (18)F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase.

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)00134-X

7 January 2021

Labeled EGFr-TK irreversible inhibitor (ML03): in vitro and in vivo properties, potential as PET biomarker for cancer and feasibility as anticancer drug.

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)00134-X

7 January 2021

Epidermal growth factor receptor dependence in human tumors: more than just expression?

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)00134-X

7 January 2021

Non-small cell lung cancers frequently express phosphorylated Akt; an immunohistochemical study.

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)00134-X

7 January 2021

Molecular genetics of small cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)00134-X

7 January 2021

Discovery of a novel Raf kinase inhibitor

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)00134-X

7 January 2021

Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)00134-X

7 January 2021

Toward a PKB inhibitor: modification of a selective PKA inhibitor by rational design

1 reference

https://api.crossref.org/works/10.1016/S0169-5002(03)00134-X

7 January 2021

10.1016/S0169-5002(03)00134-X

Identifiers

DOI

1 reference

release_tzrfhnqt2ncq3pd7u3i7uww2hm

7 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tzrfhnqt2ncq3pd7u3i7uww2hm

24 November 2022

mapped directly with Wikidata item

1 reference